CAJ | 학술논문

目的：探讨表柔比星联合紫杉醇的新辅助化疗治疗三阴性乳腺癌的疗效。方法随机选取该院2012年1月-2014年1月收治的三阴性乳腺癌患者60例，将其按照治疗方法分为观察组与对照组，每组30例。观察组以表柔比星联合紫杉醇新辅助化疗方案进行治疗，对照组以环磷酰胺联合表阿霉素新辅助化疗方案进行治疗，比较两组患者的治疗效果。结果观察组总有效率80%；对照组为73.3%，虽比较无显著差异，但观察组CR例数明显高于对照组(P<0.05)；两组在毒副反应人数上比较差异无统计学意义(P>0.05)。结论表柔比星联合紫杉醇新辅助化疗方案治疗三阴性乳腺癌效果显著，优于传统的化疗方案。
목적：탐토표유비성연합자삼순적신보조화료치료삼음성유선암적료효。방법수궤선취해원2012년1월-2014년1월수치적삼음성유선암환자60례，장기안조치료방법분위관찰조여대조조，매조30례。관찰조이표유비성연합자삼순신보조화료방안진행치료，대조조이배린선알연합표아매소신보조화료방안진행치료，비교량조환자적치료효과。결과관찰조총유효솔80%；대조조위73.3%，수비교무현저차이，단관찰조CR례수명현고우대조조(P<0.05)；량조재독부반응인수상비교차이무통계학의의(P>0.05)。결론표유비성연합자삼순신보조화료방안치료삼음성유선암효과현저，우우전통적화료방안。
Objective To investigate the effect of neoadjuvant chemotherapy with epirubicin plus paclitaxel in the treatment of three-negative breast cancer. Methods 60 patients with three-negative breast cancer admitted to our hospital from Jan-uary 2012 and January 2014 were included and divided into observation group and control group according to the treatment methods with 30 in each one. The observation group was treated with neoadjuvant chemotherapy with epirubicin plus pacli-taxel, while the control group was treated with neoadjuvant chemotherapy with cyclophosphamide plus with epirubicin. The outcomes were compared between the patients in the two groups. Results The total effective rate was 80%in the observation group and 73.3%in the control group, and no statistical difference can be found between them. While in complete remission rate, the observation group was higher than the control group(P<0.05); no statistically significant difference can be found in adverse reaction rate between the two groups (P>0.05). Conclusion Neoadjuvant chemotherapy with epirubicin plus pacli-taxel in the treatment of three-negative breast cancer has remarkable effect, and it is superior to the conventional chemotherapy regimen.